Background: In traditional Mongolian medicine, ischemic heart disease are treated by balancing the body, promoting the f low of khii and blood, improving the metabolism, suppressing inflammation, increasing heart strength, relieving pain, and treating the disease according to its actual condition. Therefore, a study was conducted to investigate the effects of traditional medicines Heart Agar-8 and Zandan-3 on ischemic heart disease. Aim: Studying the therapeutic effects of some traditional medicines used in the treatment of ischemic heart disease. Materials and Methods: Clinical trial was performed in an uncontrolled, single-centered, and open-study design. A total of 48 patients with ischemic heart disease who met the inclusion criteria participated in the study. The study was conduct ed by giving people 3 grams of Heart Agar-8 and 3 grams of Zandan-3 medicine, each once a day, for a total of 3 weeks. The results of the study were assessed before and after the study using the SAQ questionnaire, the chronic coronary syn dromes (CCS) questionnaire, 6-minute walk test, and electrocardiogram. The research was conducted in accordance with the appropriate ethical approvals (No. 24-25/03-01), (No. 2024-077) and confirmed by an informed consent form. Clinical trial research results were processed using T-test, Paired T-test. Results: A total of 48 people diagnosed with ischemic heart disease (TMK00.2) were included in the study. The average age of the study participants was 53.94±1.69, with the youngest being 44 and the oldest being 60. Regarding the gender of the respondents, 15 (31.25%) were men and 33 (68.75%) were women. When comparing pre-treatment results with post-treatment results using the SAQ, there were improvements in mobility (p<0.000), chest stability (p<0.012), chest pain (p<0.000), treatment satisfaction (p<0.001), and quality of life assessment (p<0.000). When assessing chronic cor onary syndrome in people, 44 or 91.6% of the total number of people included in the study had a level II score before treatment, while 37 or 77.08% had a level I score after treatment, which was a statistically significant difference between the pre-treatment and post-treatment indicators (p<0.034). Cardiac function was assessed by the 6-minute walk test, which was 393.9±36.73 meters before treatment, or grade II, but improved to 456.83±48.6 meters after treatment, or grade I (p<0.000). Conclusions 1. People diagnosed with ischemic heart disease have shown statistically significant results when given the traditional medicine Heart Agar-8 and Zandan-3 in combination with clinical trials. 2. The study participants experienced statistically significant improvements in mobility, usual activities, pain, and depression, improved quality of life, and increased functional status in coronary heart disease.